SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Jarushka Naidoo

Jarushka Naidoo

Beaumont RCSI Cancer Centre, Dublin

Prof. Jarushka Naidoo is Professor of Medical Oncology at RCSI University of Medicine and Health Sciences and a Consultant Medical Oncologist at the Beaumont RCSI Cancer Centre in Dublin, Ireland. A globally recognised authority on immune-related adverse events from checkpoint inhibitors in non-small cell lung cancer, she has authored over 100 publications, contributed to ASCO guidelines on the management of immunotherapy toxicity, and leads the Beaumont RCSI Irish Cancer Society Lung Outreach Programme. She serves as National Lung Cancer Lead for Cancer Trials Ireland, holds an adjunct assistant professorship at Johns Hopkins University, and is a frequent speaker at major international congresses.

Connect

Jarushka Naidoo

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates